New Stock News | Longfeng Group passes the hearing at the Hong Kong Stock Exchange, offering over 700 SKUs of its brands such as pharmaceuticals and cosmetics for sale.

According to the disclosure on May 17 by the Hong Kong Stock Exchange, LongFung Group Holdings Limited (referred to as LongFung Group) conducted a listing hearing on the main board of the Hong Kong Stock Exchange, with DBS Group as the sole sponsor. According to the prospectus, LongFung Group is a leading chain retail operator of cosmetics and health products based in Hong Kong and operating under the LongFung brand. According to Frost & Sullivan, by 2024, in terms of retail sales, the company ranks second among beauty, health, and pharmaceutical retailers in Hong Kong, with a market share of 5.8%; and in terms of retail sales, the company is the largest pharmaceutical retailer in Hong Kong, with a market share of 5.2%. Additionally, the company is also the second largest pharmaceutical and health product retailer in Hong Kong in terms of revenue, with a market share of approximately 4.2%. At the end of the feasible period, the company is committed to operating 31 retail stores and various online sales platforms under the "LongFung" brand in Hong Kong. As of November 30, 2025, LongFung Group has over 600 suppliers, including local distributors in Hong Kong and overseas suppliers mainly located in Japan, South Korea, Southeast Asia, Europe, and the United States. The company focuses on timely procurement of quality products that meet the mainstream needs of target customers, and has established a procurement office in Fukuoka, Japan, specialized in sourcing local products that appeal to target customers. In terms of products, LongFung Group is committed to providing customers with a diverse range of products beyond traditional pharmacy categories, and continuously assesses market trends to meet customer needs. Starting from beauty, health, and pharmaceutical products, the company has gradually expanded into other product categories such as snacks and pet food to attract a wider customer base including the younger generation. During the historical period, the company sold over 49,000 SKUs, and in the 2025 fiscal year, it sold approximately 28,800 SKUs, including over 6,800 SKUs of beauty products, over 4,200 SKUs of health products, over 3,000 SKUs of pharmaceutical products, and over 14,000 SKUs of other consumer products, demonstrating the breadth and depth of its product portfolio. Each store usually stocks over 8,000 SKUs, with some large stores stocking around 13,000 SKUs. With a mature retail store network and experience in consumer goods sales, the company continues to develop and launch its own brand products. As of November 30, 2025, the company has established over 40 own brands. In the first eight months of the 2026 fiscal year, its own brand products offer over 700 SKUs for sale. Financially, in the 2023 fiscal year, the 2024 fiscal year, the 2025 fiscal year, and the first eight months of the 2026 fiscal year, the company's revenue was approximately HK$1.094 billion, HK$2.021 billion, HK$2.46 billion, and HK$2.035 billion, respectively. During the same period, the company's annual profit was approximately -HK$27.14 million, HK$145 million, HK$170 million, and HK$148 million.